Publication:
Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options

Simple item page
dc.contributor.authorÇETİN, GÜVEN
dc.contributor.authorEŞKAZAN, Ahmet Emre
dc.contributor.authorAR, Muhlis Cem
dc.contributor.authorAydin, Seniz Ongoren
dc.contributor.authorFerhanoglu, Burhan
dc.contributor.authorSoysal, Teoman
dc.contributor.authorBaslar, Zafer
dc.contributor.authorAydin, Yildiz
dc.contributor.institutionauthorÇETİN, GÜVEN
dc.date.accessioned2020-10-22T20:19:24Z
dc.date.available2020-10-22T20:19:24Z
dc.date.issued2014-12-01T00:00:00Z
dc.description.abstractObjective: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels. Materials and Methods: One hundred and thirteen patients with MM were included in the study. Patients were grouped according to the regimens they received, as follows: group 1, melphalan and prednisolone (MP); group 2, vincristine, adriablastin, and dexamethasone (VAD); group 3, thalidomide plus dexamethasone; and group 4, bortezomib plus dexamethasone. BALP levels were measured before treatment and at the third and sixth months of treatment. A fifth group consisted of patients in the post-treatment remission period at study entry (no-treatment group). Results: The BALP levels at the third and sixth months of the treatment were significantly higher than the pre-treatment levels in the bortezomib and the no-treatment groups, whereas no significant difference was observed in the MP, VAD, and thalidomide groups. Conclusion: Considering that BALP is a surrogate marker of bone formation, our study suggests efficiently leads to the improvement of bone disease in myeloma than other treatment options.
dc.identifier.citationÇETİN G., EŞKAZAN A. E. , AR M. C. , Aydin S. O. , Ferhanoglu B., Soysal T., Baslar Z., Aydin Y., -Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options-, TURKISH JOURNAL OF HEMATOLOGY, cilt.31, ss.374-380, 2014
dc.identifier.doi10.4274/tjh.2013.0004
dc.identifier.pubmed25541654
dc.identifier.scopus84924573897
dc.identifier.urihttp://hdl.handle.net/20.500.12645/24654
dc.identifier.urihttp://www.journalagent.com/z4/vi.asp?pdir=tjh&plng=eng&un=TJH-38159
dc.identifier.wosWOS:000348688800006
dc.subjectMultiple myeloma
dc.titleBone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options
dc.typeArticle
dspace.entity.typePublication
local.avesis.idd65dd7b1-88e4-489b-9e50-3016ace61586
local.publication.isinternational1
relation.isAuthorOfPublicationb08a3f06-950e-41ba-bd74-ae73d014adc9
relation.isAuthorOfPublication.latestForDiscoveryb08a3f06-950e-41ba-bd74-ae73d014adc9
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bone-Specific Alkaline.pdf
Size:
208.84 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler